Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/16140
Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19
Identifiers
DOI: 10.3390/jcm9103136
eISSN: 2077-0383
WOS ID: 000585289800001
PMID: 32998337
Embase PUI: L2005150091
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Rodilla, Enrique; Saura, Alberto; Jimenez, Iratxe; Mendizabal, Andrea; Pineda-Cantero, Araceli; Lorenzo-Hernandez, Elizabeth; Fidalgo-Montero, Maria del Pilar; Lopez-Cuervo, Joaquin Fernandez; Gil-Sanchez, Ricardo; Rabadan-Pejenaute, Elisa; Abella-Vazquez, Lucy; Giner-Galvan, Vicente; Solis-Marquinez, Marta Nataya; Boixeda, Ramon; Pena-Fernandez, Andres de la; Carrasco-Sanchez, Francisco Javier; Gonzalez-Moraleja, Julio; Torres-Pena, Jose David; Guisado-Espartero, Maria Esther; Escobar-Sevilla, Joaquin; Guzman-Garcia, Marcos; Martin-Escalante, Maria Dolores; Martinez-Gonzalez, Angel Luis; Casas-Rojo, Jose Manuel; Gomez-Huelgas, RicardoPublication date
2020-10Document type
research articleCitation
Rodilla E, Saura A, Jimenez I, Mendizabal A, Pineda-Cantero A, Lorenzo-Hernandez E, et al. Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. J Clin Med. 2020 Oct;9(10):3136.Abstract
It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 +/- 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.
Publisher version
https://dx.doi.org/10.3390/jcm9103136Keywords
hypertensionCOVID-19
angiotensin-converting enzyme inhibitors (ACEIs)
angiotensin II receptor blockers (ARBs)
all-cause mortality